These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 20415232)

  • 1. [Recent clinical evidences of RAS inhibitors on chronic kidney diseases].
    Suzuki H; Takenaka T
    Nihon Jinzo Gakkai Shi; 2010; 52(2):120-4. PubMed ID: 20415232
    [No Abstract]   [Full Text] [Related]  

  • 2. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Recent advance in kidney and hypertension research].
    Kumagai H; Oda T; Ohshima N; Takechi H; Yamamoto K; Uchida T; Watanabe A; Tadano H; Matsubara H; Senda M
    Nihon Jinzo Gakkai Shi; 2012; 54(1):1-10. PubMed ID: 22413572
    [No Abstract]   [Full Text] [Related]  

  • 4. [Pharmocological therapeutics for chronic heart failure--how to use ARB (angiotensin receptor blocker].
    Kudo Y; Komuro I; Akazawa H
    Nihon Rinsho; 2007 May; 65 Suppl 5():84-9. PubMed ID: 17571370
    [No Abstract]   [Full Text] [Related]  

  • 5. [Treatment of heart failure based on large-scale clinical trials: renin-angiotensin system antagonists and beta-blockers].
    Kubota T; Takeshita A
    Nihon Rinsho; 2003 May; 61(5):801-6. PubMed ID: 12755006
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent changes in the landscape of combination RAS blockade.
    Epstein BJ; Smith SM; Choksi R
    Expert Rev Cardiovasc Ther; 2009 Nov; 7(11):1373-84. PubMed ID: 19900020
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-angiotensin therapy: new perspectives.
    Ramasubbu K; Mann DL; Deswal A
    Cardiol Clin; 2007 Nov; 25(4):573-80; vi-vii. PubMed ID: 18063161
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Add-on angiotensin receptor blocker in patients who have proteinuric chronic kidney diseases and are treated with angiotensin-converting enzyme inhibitors.
    Kanno Y; Takenaka T; Nakamura T; Suzuki H
    Clin J Am Soc Nephrol; 2006 Jul; 1(4):730-7. PubMed ID: 17699280
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A review of the current evidence for the use of angiotensin-receptor blockers in chronic heart failure.
    Erhardt LR
    Int J Clin Pract; 2005 May; 59(5):571-8. PubMed ID: 15857354
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New therapeutic strategies with combined renin-angiotensin system inhibitors for pediatric nephropathy.
    Zaffanello M; Franchini M; Fanos V
    Pharmacotherapy; 2008 Jan; 28(1):125-30. PubMed ID: 18154482
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How should renin-angiotensin system blockade be applied in chronic kidney disease for optimal renal protection?
    Zhang X; Hou FF
    Chin Med J (Engl); 2007 Feb; 120(3):243-5. PubMed ID: 17355830
    [No Abstract]   [Full Text] [Related]  

  • 12. Beneficial action of candesartan cilexetil plus amlodipine or ACE inhibitors in chronic nondiabetic renal disease.
    Homma K; Hayashi K; Kanda T; Yoshioka K; Takamatsu I; Tatematsu S; Kumagai H; Wakino S; Saruta T
    J Hum Hypertens; 2004 Dec; 18(12):879-84. PubMed ID: 15295613
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of a triple blockade of the renin-angiotensin-system in recurrent focal segmental glomerulosclerosis after kidney transplantation.
    Freiberger V; Amann K; Heemann U; Frank H
    Transpl Int; 2009 Nov; 22(11):1110-3. PubMed ID: 19497068
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual blockade of the renin-angiotensin-aldosterone system: beyond the ACE inhibitor and angiotensin-II receptor blocker combination.
    Bomback AS; Toto R
    Am J Hypertens; 2009 Oct; 22(10):1032-40. PubMed ID: 19661925
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Feasibility of combined treatment with enalapril and candesartan in advanced chronic kidney disease.
    Frimodt-Møller M; Høj Nielsen A; Strandgaard S; Kamper AL
    Nephrol Dial Transplant; 2010 Mar; 25(3):842-7. PubMed ID: 19903661
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aliskiren combined with losartan in diabetes and nephropathy.
    Lindner T
    N Engl J Med; 2008 Sep; 359(10):1068-9; author reply 1069-70. PubMed ID: 18777612
    [No Abstract]   [Full Text] [Related]  

  • 17. [Review of randomized trials of angiotensin receptor blockers in the treatment of patients with congestive heart failure].
    Rakugi H; Ogihara T
    Nihon Rinsho; 2001 Oct; 59(10):2051-61. PubMed ID: 11676153
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug dosing for renoprotection: maybe it's time for a drug efficacy-safety score?
    de Zeeuw D; Lambers-Heerspink H
    J Am Soc Nephrol; 2009 Apr; 20(4):688-9. PubMed ID: 19279124
    [No Abstract]   [Full Text] [Related]  

  • 19. Low-dose angiotensin II receptor antagonists and angiotensin II-converting enzyme inhibitors alone or in combination for treatment of primary glomerulonephritis.
    Renke M; Tylicki L; Rutkowski P; Rutkowski B
    Scand J Urol Nephrol; 2004; 38(5):427-33. PubMed ID: 15764256
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Efficacy of calcium channel blocker in hypertensive patients with chronic kidney disease].
    Morihira M; Kikuchi K; Nakagawa N; Fujino T; Hasebe N
    Nihon Jinzo Gakkai Shi; 2009; 51(4):451-5. PubMed ID: 19601552
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.